Search Drug Information, Interactions, Images, Dosage & Side Effects

Bidirectional genetic link exists between myopia, POAG 24 Mar 2023
Myopia and primary open-angle glaucoma (POAG) share a strong bidirectional, genetic, causal relationship, which is primarily driven by intraocular pressure (IOP), suggest the results of a study.

Metformin–thiazolidinedione combo best bet for AF prevention in T2D

24 Mar 2023

Time-restricted eating offers no additional benefits in adults with obesity, NAFLD

24 Mar 2023

Cinnamon helps improve lipid profile

23 Mar 2023

Higher-dose bevacizumab tied to fewer retreatments in ROP patients

23 Mar 2023

Coordinated care improves use of CVD-preventive therapies in T2D

23 Mar 2023

Use of monitoring tests remains low among prostate cancer patients under observation

23 Mar 2023

Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients

23 Mar 2023

5-ASA maintenance therapy of little help in patients with newly diagnosed CD

23 Mar 2023

Complete response to therapy higher in clinical trial than real-world metastatic RCC patients

22 Mar 2023

Wrist-worn sensor predicts elevated hs-cTnI in ACS patients

22 Mar 2023

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure 21 Mar 2023;
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.